Loading...
•
Jun 30, 2025
Personalis Q2 2025 Earnings Report
Personalis reported financial results for the second quarter ended June 30, 2025, highlighting strong clinical momentum with a 59% sequential growth in test volume.
Key Takeaways
Personalis experienced a challenging second quarter in 2025 with a significant revenue decline of 24% year-over-year, primarily due to expected decreases from Natera and a reduction in pharma tests and services. Despite these headwinds, the company demonstrated strong clinical adoption, with a 59% sequential increase in clinical test volume, driven by the NeXT Personal® platform and compelling clinical data presentations. The net loss widened compared to the previous year, and the gross margin decreased.
Total revenue for Q2 2025 was $17.2 million, a 24% decrease compared to $22.6 million in Q2 2024.
Clinical test volume saw a significant 59% sequential increase, with 3,478 clinical tests delivered in Q2 2025.
Gross margin declined to 27.6% in Q2 2025 from 35.6% in Q2 2024, primarily due to lower revenue volume and increased unreimbursed clinical test costs.
Net loss for Q2 2025 was $20.1 million, compared to a net loss of $12.8 million in Q2 2024.
Revenue by Segment
Forward Guidance
Personalis has updated its full-year 2025 guidance, reducing total company revenue expectations and increasing the projected net loss and cash usage, while narrowing the range for clinical tests reimbursed.
Positive Outlook
- Continued focus on the 'Win-in-MRD' strategy, aiming for Medicare coverage for two indications.
- Anticipated growth in clinical test volume, supported by ongoing investments in the NeXT Personal platform.
- Expansion of strategic collaboration with Tempus AI, Inc. to include colorectal cancer, a major new indication.
- Ongoing generation of world-class clinical evidence, such as pivotal data presented at ASCO 2025, demonstrating the value of NeXT Personal.
- Expected revenue from population sequencing and enterprise sales to be in the range of $15 million to $16 million for the full year 2025.
Challenges Ahead
- Total company revenue for full year 2025 is now expected to be in the range of $70 million to $80 million, reduced from the previous guidance of $80 million to $90 million.
- Revenue from pharma tests and services, and all other customers, for full year 2025 is now expected to be in the range of $52 million to $58 million, reduced from $62 million to $64 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...